| Dr Christopher Don Jenck, OD | |
|
800 Main Ave Ste A, Tillamook, OR 97141-3760 | |
| (503) 842-5568 | |
| (503) 842-1122 |
| Full Name | Dr Christopher Don Jenck |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | 800 Main Ave Ste A, Tillamook, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497470199 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 4651 (Oregon) | Primary |
| Provider Name | Tvc Od, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1790215192 PECOS PAC ID: 1456619360 Enrollment ID: O20171226001850 |
News Archive
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
In a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog, Jamie Elizabeth Rosen, media and communications manager at Aeras, interviews Steven Reed, founder, president, and chief scientific officer of the Infectious Disease Research Institute (IDRI), "a 120-person non-profit biotech committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty."
ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its new translational medicine unit in Manchester, UK. The unit is the first deliverable from a collaborative agreement between ICON and the Central Manchester University Hospitals Foundation (CMFT) to develop purpose-built translational medicine facilities on the newly-developed Manchester Royal Infirmary (MRI) campus.
Representative Paul Ryan is rebutting critics of his plan to turn Medicare into a "premium support" program, pointing to two existing programs that he says prove his approach would be better for beneficiaries. Don't believe it. The two programs he cites as prototypes — the insurance program for members of Congress and the Medicare prescription drug program — differ in critical respects from his proposal to sharply limit federal spending. The losers will be the beneficiaries who have to pay more.
Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Don Jenck, OD 800 Main Ave Ste A, Tillamook, OR 97141-3760 Ph: (503) 842-5568 | Dr Christopher Don Jenck, OD 800 Main Ave Ste A, Tillamook, OR 97141-3760 Ph: (503) 842-5568 |
News Archive
Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
In a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog, Jamie Elizabeth Rosen, media and communications manager at Aeras, interviews Steven Reed, founder, president, and chief scientific officer of the Infectious Disease Research Institute (IDRI), "a 120-person non-profit biotech committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty."
ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its new translational medicine unit in Manchester, UK. The unit is the first deliverable from a collaborative agreement between ICON and the Central Manchester University Hospitals Foundation (CMFT) to develop purpose-built translational medicine facilities on the newly-developed Manchester Royal Infirmary (MRI) campus.
Representative Paul Ryan is rebutting critics of his plan to turn Medicare into a "premium support" program, pointing to two existing programs that he says prove his approach would be better for beneficiaries. Don't believe it. The two programs he cites as prototypes — the insurance program for members of Congress and the Medicare prescription drug program — differ in critical respects from his proposal to sharply limit federal spending. The losers will be the beneficiaries who have to pay more.
Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.
› Verified 2 days ago
Lee Michael Johnson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 800 Main Ave Ste A, Tillamook, OR 97141 Phone: 503-842-5568 | |
Lighthouse Vision Care, P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 310 Stillwell Ave, Tillamook, OR 97141 Phone: 503-842-6363 Fax: 503-842-6204 | |
Coastal Eyecare Tillamook Llc Optometrist Medicare: Medicare Enrolled Practice Location: 102 Main Ave, Tillamook, OR 97141 Phone: 503-374-0399 Fax: 503-374-0374 | |
Dr. Eric Halperin, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 800 Main Ave, Suite A, Tillamook, OR 97141 Phone: 503-842-5568 Fax: 503-842-1122 | |
Rowland Vision Care Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 2500 Main Ave N, Tillamook, OR 97141 Phone: 503-453-2940 | |
Eyes Of Oregon Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 102 Main Ave, Tillamook, OR 97141 Phone: 503-842-4202 |